👀 We used a visual masking paradigm and found that healthy volunteers under ketamine were less able to perceive a digit.

🧠 These effects were related to a decreased early brain activity in EEG (N1) and to the intensity of experienced psychotic-like symptoms.

Moreover, improvement was more robustly predicted by baseline neural and clinical features under antidepressant compared to placebo.

However, the intensity of antidepressant and placebo response significantly differs (in previous papers on this dataset, scale level measures of improvement could not distinguish between the two).

We applied principal component analysis (PCA) on the variations of items from multiple clinical scales and strikingly observed a similar pattern of clinical improvement across antidepressant and placebo arms.

We explored clinical response in patients with major depressive disorder from the EMBARC dataset.

Yesterday, it was the first edition of the National Symposium of the #Psychedelic Medicine Section of the AFPBN and it was a huge success!!

🌟 Stars of the field shared with us the latest news, "avant première" results from French and international research, opening inspiring perspectives.

🍿 Carton plein !!
Notre symposium du 5 juin sur la #médecine #psychédélique affiche COMPLET pour le présentiel !
Il est encore possible de vous inscrire pour suivre l'événement dans sa version #distancielle en cliquant sur ce lien ➡️ www.comtoevidence.com/evenement/93/

Happy New Year!

psychiatryonline.org/toc/ajp/182/1